Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002337
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease
Sponsor:
Otsuka America Pharmaceutical
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Phase I Safety and Tolerability Study of Four Doses of OPC-8212 Vesnarinone in Advanced HIV Disease
Status:
COMPLETED
Status Verified Date:
1996-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the safety and tolerability of four doses of oral vesnarinone in patients with advanced HIV disease
Detailed Description:
Fourteen patients per dose level receive vesnarinone at 1 of 4 doses for 12 weeks At least seven patients at a given dose level must have completed 4 weeks of treatment before dose is escalated in subsequent patients
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 22-93-252 | None | None | None |